Sugi Predict

Sugi Predict / Compounds / SCHEMBL2555419

SCHEMBL2555419

SCHEMBL2555419

O=Cc1ccnc(NC(=O)O)c1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.42
▸ RAB9A P51151 7/20 0.40
▸ NPC1 O15118 6/20 0.40
▸ SORT1 Q99523 2/20 0.39
▸ NR3C2 P08235 3/20 0.39
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ PKM P14618 2/20 0.38
▸ UNG P13051 1/20 0.38
▸ ACVRL1 P37023 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ GSK3B P49841 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ GCK P35557 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29951814 0.84 L3MBTL1 (0.52) ACVRL1
SCHEMBL7365972 0.84 L3MBTL1 (0.52) ACVRL1
SCHEMBL22809551 0.80 TYK2 (0.50) RAB9ANPC1SMN1; SMN2ACVRL1TP53
SCHEMBL5777715 0.80 LMNA (0.47) RAB9ANPC1GSK3B
SCHEMBL22809499 0.80 ACVRL1 (0.58) ACVRL1GSK3B
SCHEMBL14022342 0.80 FGFR4 (0.46) GCK
SCHEMBL18266478 0.80 JAK2 (0.50) RAB9ANPC1SMN1; SMN2ACVRL1TP53
SCHEMBL22809622 0.78 RAB9A (0.45) RAB9ANPC1SMN1; SMN2TP53MEN1
SCHEMBL1258539 0.77 ATR (0.47) RAB9AGSK3B
SCHEMBL18266676 0.77 ALDH1A1 (0.42) NR3C2GSK3BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024121427-A1 THERAPEUTIC COMPOUNDS SANOFI (FR) 2024-06-13 — — WO disclosed
EP-4347607-A1 PENICILLIN-BINDING PROTEIN INHIBITORS Venatorx Pharmaceuticals, Inc. (US) 2024-04-10 — — EP disclosed
US-11918656-B2 Antibody-drug-conjugate and its use for the treatment of cancer PIERRE FABRE MEDICAMENT (FR) 2024-03-05 — — US disclosed
US-11661457-B2 IGF-1R antibody-drug-conjugate and its use for the treatment of cancer PIERRE FABRE MEDICAMENT (FR) 2023-05-30 — — US disclosed
US-20230002316-A1 DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS PIERRE FABRE MEDICAMENT (FR) 2023-01-05 — — US disclosed
EP-3607996-B1 ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER PF MEDICAMENT (FR) 2023-01-04 — — EP disclosed
US-11517625-B2 Antibody-drug-conjugate and its use for the treatment of cancer PIERRE FABRE MEDICAMENT (FR) 2022-12-06 — — US disclosed
EP-3388427-B1 DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS PF MEDICAMENT (FR) 2022-01-19 — — EP disclosed
US-11219693-B2 Antibody-drug-conjugate and its use for the treatment of cancer PIERRE FABRE MEDICAMENT (FR) 2022-01-11 — — US disclosed
US-20210107868-A1 DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS PIERRE FABRE MEDICAMENT (FR) 2021-04-15 — — US disclosed
WO-2015162293-A1 ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2015-10-29 — — WO disclosed
WO-2015162291-A1 IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2015-10-29 — — WO disclosed
US-9024041-B2 P38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2015-05-05 — — US disclosed
WO-2014174064-A1 DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS PIERRE FABRE MEDICAMENT (FR) 2014-10-30 — — WO disclosed
WO-2014174060-A1 DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS PIERRE FABRE MEDICAMENT (FR) 2014-10-30 — — WO disclosed
WO-2014174062-A1 DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS PIERRE FABRE MEDICAMENT (FR) 2014-10-30 — — WO disclosed
US-20130040962-A1 P38 MAP Kinase Inhibitors RESPIVERT LTD (GB) 2013-02-14 — — US disclosed
EP-2556068-A1 P38 MAP KINASE INHIBITORS Respivert Limited (GB) 2013-02-13 — — EP disclosed
WO-2011124930-A1 P38 MAP KINASE INHIBITORS RESPIVERT LIMITED (GB) 2011-10-13 — — WO disclosed
WO-2001002364-A1 NEW NPY ANTAGONISTS ASTRAZENECA AB (SE) 2001-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11517625-B2 Antibody-drug-conjugate and its use for the treatment of cancer DDOST, DAD1, KRTCAP2 EGFR 232/4885RAB9A 2321/4885NPC1 466/4885
US-20230002316-A1 DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS NR1H4, HCAR3, VDR EGFR 449/4885RAB9A 2564/4885NPC1 70/4885
US-11219693-B2 Antibody-drug-conjugate and its use for the treatment of cancer DAD1, DDOST, KRTCAP2 EGFR 219/4885RAB9A 2392/4885NPC1 742/4885
US-11918656-B2 Antibody-drug-conjugate and its use for the treatment of cancer DDOST, DAD1, KRTCAP2 EGFR 232/4885RAB9A 2321/4885NPC1 466/4885
US-11661457-B2 IGF-1R antibody-drug-conjugate and its use for the treatment of cancer IGF1R, IGFBP1, IGFBP5 EGFR 30/4885RAB9A 1984/4885NPC1 769/4885
US-20130040962-A1 P38 MAP Kinase Inhibitors MAPK15, MAPK1, MAP3K15 EGFR 3376/4885RAB9A 880/4885NPC1 3262/4885
US-20210107868-A1 DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS NR1H4, HCAR3, VDR EGFR 449/4885RAB9A 2564/4885NPC1 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.